ClinicalTrials.gg

Program

OTS-412

A development code.

Its studies are led by Bionoxx.

Furthest: phase 1, since Jul 30, 20253 company-led studies, 2 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bionoxx32 open or runningphase 1since Jul 30, 2025Jul 30, 2025Dec 2028phase 1 · NCT07190833

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 30, 2025First study: phase 1 study in Treatment-Refractory Solid TumorsFirst studyNCT07170592 · 24 planned
  2. Sep 17, 2025Phase 1 study in Treatment-Refractory Solid TumorsNCT07190833 · 21 planned · South Korea
  3. Nov 16, 2025Early phase 1 study in Healthy VolunteerNCT07302945 · 1 enrolled · South Korea

Ahead

  1. Dec 2028Primary completion: phase 1 study in Treatment-Refractory Solid TumorsNCT07190833
  2. Dec 2028Primary completion: phase 1 study in Treatment-Refractory Solid TumorsNCT07170592

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07302945Healthy Volunteer · South KoreaEarly 1CompletedJan 14, 20221
NCT07190833Treatment-Refractory Solid Tumors · South Korea1RecruitingDec 202821
NCT07170592Treatment-Refractory Solid Tumors1Not yet recruitingDec 202824

How it is read

Names in the registry

  • “OTS-412”, 8 entries

Codes read as this program: OTS412.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.